Cancer Chemotherapy and Pharmacology

, Volume 53, Issue 2, pp 141–150

Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats

  • Shri N. Giri
  • Mohammed Ali Al-Bayati
  • Xiaogu Du
  • Edward Schelegle
  • F. Charles Mohr
  • Solomon B. Margolin
Original Article



Doxorubicin (DXR) is an anthracycline glycoside with a broad spectrum of therapeutic activity against various tumors. However, the clinical use of DXR has been limited by its undesirable systemic toxicity, especially in the heart and kidney. This study was designed to test the effectiveness of dietary intake of pirfenidone (PD) against DXR-induced cardiac and renal toxicity.


Male Sprague Dawley rats were placed into four treatment groups: saline injected intraperitoneally (i.p.) plus regular diet (SA+RD); DXR i.p. plus regular diet (DXR+RD); saline i.p. plus the same diet mixed with 0.6% PD (SA+PD); and DXR i.p. plus the same diet mixed with 0.6% PD (DXR+PD). The animals were fed regular or regular plus PD diets 3 days prior to i.p. injections of either saline or DXR and continuing throughout the study. A total dose of DXR (16.25 mg/kg) or an equivalent volume of saline was administered in seven injections (2.32 mg/kg per injection) three times per week with an additional dose on the 12th day. At 25 days following the last DXR or saline injection, some animals were anesthetized for the measurement of cardiac and pulmonary function, and others were killed by an overdose of pentobarbital. At the time the animals were killed, abdominal fluid was collected. Kidney and heart were removed, weighed, fixed with 10% formalin or frozen in liquid nitrogen. The fixed tissues were used for histological examination and the frozen tissues were used for biochemical studies.


The average volumes of abdominal fluid in the DXR+RD and DXR+PD groups were 9.42 ml and 3.42 ml and the protein contents of abdominal fluid in the DXR+RD and DXR+PD groups were 218 mg and 70 mg, respectively. A 12.5% mortality occurred in the DXR+RD group as compared to 0% in DXR+PD group. There were no changes in any of the cardiac or pulmonary physiological parameters in any of the four groups. The changes in the heart and kidney of the DXR+RD group included reduction in organ weight, increase in hydroxyproline content of heart, increase in hydroxyproline, and lipid peroxidation in the kidney and plasma, and increase in protein concentration in urine as compared to rats in the control, SA+RD and SA+PD groups. Treatment with PD abrogated the DXR-induced increases in hydroxyproline content in the heart and kidney, lipid peroxidation of the kidney and plasma, and protein content of the urine in the DXR+PD group. DXR treatment alone caused disorganization of cardiac myofibrils, vacuolization of the myofibers, and renal tubular dilation with protein casts in both the cortical and medullary regions. Treatment with PD minimized the DXR-induced histopathological changes of heart and kidney in the DXR+PD group.


Treatment with PD reduced the severity of DXR-induced toxicity as assessed by reduced mortality, diminished volume of recovered fluid in the abdominal cavity, and severity of cardiac and renal lesions at both the biochemical and morphological levels. These results indicate that PD has the potential to prevent DXR-induced cardiac and renal damage in humans on DXR therapy.


Doxorubicin Pirfenidone Antioxidant Heart Kidney 


  1. 1.
    Al-Bayati MA, Xie Y, Mohr FC, Margolin SB, Giri SN (2002) Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol 64:517CrossRefPubMedGoogle Scholar
  2. 2.
    AL-Majed AA, Gado AM, AL-Shabanah OA, Mansour MA (2002) Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin. Pharmacol Res 46:499CrossRefPubMedGoogle Scholar
  3. 3.
    Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141PubMedGoogle Scholar
  4. 4.
    Barchowsky A, Dudek EJ, Treadwell MD, Wetterhan KE (1996) Arsenic induces oxidant stress and NF-kB activation in cultured aortic endothelial cells. Free Radic Biol Med 18:321Google Scholar
  5. 5.
    Bertani T, Remuzzi G, Rocchi G, Delaini F, Sacchi G, Falchetti M, Donnati MB (1984) Steroids and adriamycin nephrosis. Appl Pathol 2:32PubMedGoogle Scholar
  6. 6.
    Bizzi A, Ceriani L, Gerundino M, Spina A, Tacconi MT, Venorani E (1983) Adriamycin causes hyperlipidemia as a consequence of nephrotoxicity. Toxicol Lett 18:29CrossRefGoogle Scholar
  7. 7.
    Blum RH (1975) An overview of studies with Adriamycin (NSC) in the United States. Cancer Chemotherapy Rep 6:247Google Scholar
  8. 8.
    Bristow MR (1982) Toxic cardiomyopathy due to doxorubicin. Hosp Pract 17:101Google Scholar
  9. 9.
    Burke JF, Laucius F, Brodovsky HS, Soriano RZ (1977) Doxorubicin hydrochloride-associated renal failure. Arch Intern Med 137:385CrossRefPubMedGoogle Scholar
  10. 10.
    Bus JS, Gibson JE (1979) Lipid peroxidation and its role in toxicology. In: Hodgson E, Bend JR, Philpot RM (eds) Reviews in biochemical toxicology. Elsevier North Holland, New York, p 125Google Scholar
  11. 11.
    Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin SB, Lefkowitz SS (1998) Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunol 20:685CrossRefGoogle Scholar
  12. 12.
    Chabner BA, Ryan DP, Paz-Ares L, Carbonero RG, Calabresi P (2001) Antineoplastic agents. In: Hardman JG, Limbird LE, Gilman AG (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, p 1389Google Scholar
  13. 13.
    Chopra S, Pillai KK, Husain SZ, Giri DK (1995) Propolis protects against doxorubicin-induced myocardiopathy in rats. Exp Mol Pathol 62:190CrossRefPubMedGoogle Scholar
  14. 14.
    DeAtley SM, Aksenov MY, Aksenova MV, Jordan B, Carney JM, Butterfield DA (1999) Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 134:51CrossRefPubMedGoogle Scholar
  15. 15.
    Facchinetti T, Delaini F, Salmona M, Donati MB, Feuerstein S, Wendel A (1983) The influence of selenium intake on chronic adriamycin toxicity and lipid peroxidation in rats. Toxicol Lett 15:128CrossRefGoogle Scholar
  16. 16.
    Ferrans VJ (1978) Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62:955PubMedGoogle Scholar
  17. 17.
    Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V (1999) Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 18:169Google Scholar
  18. 18.
    Giri SN, Biring I, Nguyen T, Wang Q, Hyde DM (2002) Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice. Nitric Oxide 7:109CrossRefPubMedGoogle Scholar
  19. 19.
    Goodman J, Hockstein P (1977) Generation of free radicals and lipid peroxidation by redox cycle of adriamycin and daunorubicin. Biochem Biophys Res Commun 77:797PubMedGoogle Scholar
  20. 20.
    Gurujeyalakshmi G, Wang Y, Giri SN (2000) Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kB in mice. J Pharmacol Exp Ther 293:82PubMedGoogle Scholar
  21. 21.
    Gurujayalakshmi G, Wang Y, Giri SN (2002) Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 4:399CrossRefGoogle Scholar
  22. 22.
    Henkel T, Mechleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA (1993) Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 365:182PubMedGoogle Scholar
  23. 23.
    Hinshaw L, Olson P, Kuo G (1989) Efficacy of post-treatment with anti-TNF monoclonal antibody in preventing the pathophysiology and lethality of sepsis in the baboon. Circ Shock 27:362Google Scholar
  24. 24.
    Iliskovic N, Hasinoff BB, Malisza KL, Li T, Danelisen I, Singal PK (1999) Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem 196:43CrossRefPubMedGoogle Scholar
  25. 25.
    Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN (1995) Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125:779PubMedGoogle Scholar
  26. 26.
    Iyer SN, Hyde DM, Giri SN (2000) Anti-inflammatory effect of pirfenidone in the bleomycin–hamster model of lung inflammation. Inflammation 24:477CrossRefPubMedGoogle Scholar
  27. 27.
    Janssen Y, Barchowsky A, Treadwell M, Driscoll KE, Mossman BT (1995) Asbestos induces nuclear factor B (NF-kappa B) DNA binding activity and NF-kappa B dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci U S A 92:8458PubMedGoogle Scholar
  28. 28.
    Kehrer JP, Margolin SB (1997) Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett 90:125CrossRefPubMedGoogle Scholar
  29. 29.
    Kitada M, Horie T, Awazu S (1994) Chemiluminescence associated with doxorubicin-induced lipid peroxidation in rat heart mitochondria. Biochem Pharmacol 48:93PubMedGoogle Scholar
  30. 30.
    Kojima S, Icho T, Hayashi M, Kajiwara Y, Kitabatake K, Kubota K (1993) Inhibitory effect of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J Pharmacol Exp Ther 266:699Google Scholar
  31. 31.
    Kunitoma M, Yamaguchi Y, Matsushima K, Futagawa Y, Bando Y (1985) Hyperlipidemic effects of adriamycin in rats. Jpn J Pharmacol 39:323PubMedGoogle Scholar
  32. 32.
    Leff JA, Wilke CP, Hybertson BM, Shanley CJ, Repine JE (1993) Postinsult treatment with N-acetylcysteine decreases IL-1 induced neutrophil influx and lung leak in rats. Am J Physiol 265:L501PubMedGoogle Scholar
  33. 33.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265Google Scholar
  34. 34.
    Mansoor JK, Hyde DM, Schelegle ES (1997) Pulmonary vagal reflexes breathing pattern are not altered in elastase-induced emphysema in rats. Exp Lung Res 23:441PubMedGoogle Scholar
  35. 35.
    McManus JFA, Mowry RW (1960) Staining methods, histologic and histochemical. Paul B. Hoeber, Medical Division of Harper and Brothers, New York, p 223Google Scholar
  36. 36.
    Minotti G, Ronci R, Salvatorelli E, Menna P, Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory protein 1 and 2 in cardiomyocytes: evidence from distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422PubMedGoogle Scholar
  37. 37.
    Miric G, Dallemagne C, Endre Z, Margolin SB, Taylor SM, Brown L (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133:687PubMedGoogle Scholar
  38. 38.
    Misra HP, Rabideau C (2000) Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 204:119CrossRefPubMedGoogle Scholar
  39. 39.
    Montilla P, Tunez I, Munoz MC, Lopez A, Soria JV (1997) Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration. Nephron 76:345PubMedGoogle Scholar
  40. 40.
    Mostafa AM, Nagi MN, Al Rikabi AC, Al-Shabanah OA, El-Kashef HA (1999) Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicin treatment in rats. Res Commun Mol Pathol Pharmacol 106:193PubMedGoogle Scholar
  41. 41.
    Ohkawa H, Ohismi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Biochemistry 95:351Google Scholar
  42. 42.
    Robison TW, Giri SN, Wilson DW (1989) Effects of chronic administration of doxorubicin on myocardial creatine phosphokinase and antioxidant defenses and levels of lipid peroxidation in tissues and plasma of rats. J Biochem Toxicol 4:87PubMedGoogle Scholar
  43. 43.
    Salch D, Barnes PJ, Giad A (1997) Increased production of potent oxidant peroxy nitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155:1763PubMedGoogle Scholar
  44. 44.
    Schreck R, Albermann K, Baurel PA (1992) Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (review). Free Radic Res Commun 17:221PubMedGoogle Scholar
  45. 45.
    Sun Y, Oberley LW (1966) Redox regulation of transcriptional activators. Free Radic Biol Med 21:335Google Scholar
  46. 46.
    Tada S, Nakamuta M, Enjoji M (2001) Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Exp Pharmacol Physiol 133:687Google Scholar
  47. 47.
    Tracy KJ, Beutler B, Lowry SF, et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470Google Scholar
  48. 48.
    Woessner JF Jr (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 93:440Google Scholar
  49. 49.
    Zima T, Tesar V, Stipek S, Crkovska J, Poledne R, Teminova J, Platenik J, Rychlik I, Merta M, Nemecek K (1997) The influence of cyclosporin on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron 75:464PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Shri N. Giri
    • 1
    • 5
  • Mohammed Ali Al-Bayati
    • 1
  • Xiaogu Du
    • 1
  • Edward Schelegle
    • 2
  • F. Charles Mohr
    • 3
  • Solomon B. Margolin
    • 4
  1. 1.Department of Molecular Biosciences, School of Veterinary MedicineUniversity of CaliforniaDavisUSA
  2. 2.Anatomy, Physiology and Cell Biology, School of Veterinary MedicineUniversity of CaliforniaDavisUSA
  3. 3.Pathology, Microbiology and Immunology, School of Veterinary MedicineUniversity of CaliforniaDavisUSA
  4. 4.Marnac, Inc.DallasUSA
  5. 5.Solanan, Inc.DallasUSA

Personalised recommendations